Chiesi Farmaceutici S.p.A.
PharmaParma, Italy, Italy · Est. 1935 · 6,000 employees
Chiesi Farmaceutici is an Italian pharmaceutical company specializing in respiratory diseases, rare diseases, and primary care therapies.
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
3
Indications↗
Distinct diseases across all programs
182
Clinical Trials↗
All sponsored trials (all statuses)
2
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Phase 33
Phase 21
By Therapeutic Area
top 3
Rare Disease
250%
Dermatology
125%
Respiratory
125%
R&D Momentum
65/100
Pipeline Velocity
34/100
Trial Completion Rate
87/100
Pipeline Concentration
38/100
Pipeline Freshness
81/100
Strategic Signals
- ↗Mature portfolio may be looking to in-license early assets
- ↗Active in Dermatology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 27, 2026
Completed
A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Ascending Doses in Healthy Volunteers and One Single Dose in Adult Subjects With Bronchiectasis, Followed by a Placebo-controlled, Repeated Dose, 3-way Cross-over in Adult Subjects With Bronchiectasis
Oct 23, 2026
Recruiting
Multinational Database Cohort Study to Assess Adverse Cardiovascular and Cerebrovascular Outcomes in Patients With COPD Initiating a Fixed Triple Therapy Containing BDP, FF and GB Administered Via DPI Compared to pMDI
Earlier
Oct 17, 2026TrialA Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab),in Participants With Idiopathic Pulmonary Fibrosis
Oct 14, 2026TrialA Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF10136, Administered Via Dry Powder Inhaler, After Single Ascending Dose in Healthy Subjects, Multiple Ascending Doses in Mild Asthmatic Subjects and Followed by a Repeated Dose in One Cohort of Moderate-to-Severe Asthmatic Subjects
Oct 6, 2026TrialA 52-Week, Randomised, Double-Blind, Double-Dummy, Multinational, Multicenter, Active-Controlled, 2-Arm Parallel Group Study Comparing CHF5993 100/6/12.5 μg pMDI (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide) to Seretide® Evohaler® 125/25 μg pMDI (Fixed Combination of Fluticasone Propionate/Salmeterol Xinafoate) in Adolescent Subjects With Uncontrolled Asthma on Medium Doses of Inhaled Corticosteroids in Combination With Long-Acting β2-Agonists
Sep 29, 2026TrialA Long-term Non-interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez
Sep 22, 2026TrialA Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Sep 18, 2026TrialA Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF6467 After Single and Repeated Ascending Doses by Intranasal Route in Healthy Adult Subjects
3 more events
Sep 11, 2026TrialAssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS); Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.
Sep 11, 2026TrialA 12-week Double-blind, Multicentre, Randomised, Active-controlled, 2-arm, Parallel-group Clinical Trial to Evaluate the Safety of CHF5993 pMDI 200/6/12.5 μg HFA-152a, Compared to CHF5993 pMDI 200/6/12.5 μg HFA-134a, in Subjects With Asthma.
Sep 11, 2026TrialMulticentre Observational, Prospective Cohort Study Including Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Who Receive Cangrelor i.v. Transitioning to Clopidogrel, Prasugrel or Ticagrelor Per os
Details
Company Info
Company Overview
—
Mkt Cap
$2.3B
Revenue
—
Cash
CEOStefano Gobbato
Founded1935
Employees6,000
HQParma, Italy, Italy
Websitechiesi.com
LinkedInCompany Page
Therapeutic Focus
RespiratoryRare DiseasesSpecialty CarePrimary Care
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Dermatology
Rare Disease
Respiratory
Regulatory
Regulatory Timeline
19991 event
FDANov 18
CUROSURF — CUROSURF
Application BLA020744 (BLA)
20141 event
FDAFeb 24
Myalept — MYALEPT
Application BLA125390 (BLA)
20181 event
FDAOct 5
REVCOVI — REVCOVI
Application BLA761092 (BLA)
20231 event
FDAMay 9
ELFABRIO — ELFABRIO
Application BLA761161 (BLA)
20261 event
FDAFeb 25
Juxtapid — JUXTAPID
Application NDA203858 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)